Marker Sequential Test (MaST) design

Clinical Trials

Volumn 11, Issue 1, 2014, Pages 19-27

  Freidlin, Boris ^a   Korn, Edward L ^a   Gray, Robert ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FALSE POSITIVE REACTIONS; HUMANS; MODELS, STATISTICAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN;

EID: 84893911283     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513503739     Document Type: Article

References (16)

1. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with biomarkers. J Clin Oncol. 2012 ; 30: 3304-09
2. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004 ; 10: 6759-63
3. Enrichment strategies for clinical trials to support approval of human drugs and biological products, FDA Draft Guidance. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM332181.pdf (2012).
4. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst. 2010 ; 102: 152-60
5. Simon R. Clinical trials for predictive medicine. Stat Med. 2012 ; 31: 3031-40
6. Rothmann MD, Zhang JJ, Lu L, Fleming TR. Testing in a prespecified subgroup and the intent-to-treat population. Drug Inf J. 2012 ; 46: 175-79
7. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013 ; 31: 3158-3161
8. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol. 2010 ; 28: 4697-705
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 ; 11: 521-29
10. Simon R. The use of genomics in clinical trial design. Clin Cancer Res. 2008 ; 14: 5984-93
11. Freidlin B, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005 ; 11: 7872-78
12. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 ; 27: 5538-46
13. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 ; 35 (3). 549-56
14. Lan KK, DeMets DL. Changing frequency of interim analysis in sequential monitoring. Biometrics. 1989 ; 45 (3). 1017-20
15. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010 ; 7 (3). 197-208
16. Karuri SW, Simon R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Stat Med. 2012 ; 31: 901-04